Search | Clinical Trials Finder

Conditions: Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Legg-Calvé-Perthes Disease, Osteochondral Lesion, Hip Dysplasia
Interventions: ReNew Hip Implant; Device
Lead sponsor: Cytex Therapeutics, Inc.; Other
Eligibility: 14 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Adrenoleukodystrophy (ALD), Krabbe Disease, Metachromatic Leukodystrophy (MLD), Sphingolipidoses, Peroxisomal Disorders
Interventions: Campath-1H, Cyclophosphamide, Busulfan, Allogeneic stem cell transplantation, Cyclosporine A, Mycophenolate Mofetil; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
Interventions: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452; Biological · Device
Lead sponsor: Daniel Bauer; Other
Eligibility: 13 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 292
States / cities: Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more

Conditions: Degenerative Disc Disease
Interventions: Anterior Cervical Discectomy and Fusion, Posterior Cervical Stabilization System (PCSS); Procedure · Device
Lead sponsor: Providence Medical Technology, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Encinitas, California • Los Gatos, California + 14 more

Conditions: Dwarfism, Turner's Syndrome
Interventions: Humatrope, Oxandrolone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years to 14 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2007
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Avascular Necrosis, Congenital Hip Dysplasia, Traumatic Arthritis
Interventions: Trilogy AB Acetabular Hip Implant System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Philadelphia, Pennsylvania

Conditions: Growth Hormone Deficiency, Dwarfism
Interventions: Dextromethorphan and Caffeine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 4 Years to 14 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 4
States / cities: San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 11
States / cities: Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more

Conditions: Hypophosphatasia (HPP)
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 6 more

Conditions: Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions: Aquamantys, standard electrocautery (Bovie); Device
Lead sponsor: Joint Implant Surgeons, Inc.; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: Psoriatic Arthritis, Psoriasis
Interventions: apremilast; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, Fanconi Anemia, Previously Treated Myelodysplastic Syndromes
Interventions: fludarabine phosphate, cyclosporine, total-body irradiation, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, mycophenolate mofetil; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Nashville, Tennessee + 2 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 506
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC); Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Craniosynostosis
Interventions: high dose TXA, Low dose TXA; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Months to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Germ Cell Tumors, Ewings Sarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions: Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 29 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Osteogenesis Imperfecta
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 127 participants
Timeline: 2004 – 2007
U.S. locations: 10
States / cities: Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more

Conditions: Anemia, Aplastic, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Kostmann Syndrome
Interventions: Allogeneic stem cell transplant; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Illness, Hematologic Malignancy, Bone Marrow Transplant Infection, Oncology, Sickle Cell Disease
Interventions: Guided Imagery, Virtual Reality; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 8 Years to 25 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Milwaukee, Wisconsin • Wauwatosa, Wisconsin

Conditions: Proteus Syndrome
Interventions: MK-7075 (miransertib); Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adult Rhabdomyosarcoma, Lung Metastases, Metastatic Ewing Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage IV Adult Soft Tissue Sarcoma, Stage IV Wilms Tumor, Stage V Wilms Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: intensity-modulated radiation therapy; Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 29 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: entinostat; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Adrenal Hyperplasia, Congenital
Interventions: Not listed
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 20 Years to 35 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Early Feasibility Study of Cartilage Defect Repair

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD

The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome

Trilogy AB Acetabular Hip System Post Approval Study

rhGH Therapy on Hepatic Drug Metabolism

Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

Apremilast Pregnancy Exposure Registry

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta

Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias

Distracting Through Procedural Pain and Distress

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

MS-275 in Treating Patients With Hematologic Cancer

Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia